meta|evidence oncology

Living systematic review and meta-analysis

metastatic/advanced UC (mUC) - 2nd Line (L2)
mUC - L2 - all population 2
mUC - L2 - PDL1 positive 3

immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
pembrolizumab based treatment
pembrolizumab alone

versus all
vs chemotherapy
vs Standard of Care (SoC)

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded

Study		Exclusion reasons	Remarks	Reference(s)
Empty list - no studies excluded

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -